StemLab Inc. (XKON:A258540) announced private placement of 3rd and 4th series unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 4,000,000,000 and KRW 1,000,000,000, respectively aggregate gross proceeds of KRW 5,000,000,000 on June 21, 2019. The series 3 bonds will include participation from DAYLI Partners for KRW 2,000,000,000, IBK Capital Corporation for KRW 1,000,000,000, Yongsoo Kim for KRW 900,000,000, and Blueotus Co., Ltd. for KRW 100,000,000, and series 4 bonds will include participation from DB Asset Management Co., Ltd. for KRW 1,000,000,000. The series 3 bonds will mature on June 27, 2022, and series 4 bonds will mature on July 18, 2022. The bonds does not bear any interest and bears yield to maturity of 5%. The bonds will be convertible into 232,556 shares representing 9.32% stake at a fixed conversion price of KRW 21,500 per share. The series 3 bonds will be converted between June 28, 2020 and June 26, 2022 and series 4 between July 19, 2020 and July 17, 2022. The subscription date is June 21, 2019 and expected payment date for series 3 bonds is June 28, 2019 and series 4 bonds for July 19, 2019. The transaction has been approved by the board of directors of the company. On June 27, 2019, the company has changed conversion period end date for series 3 bonds to May 27, 2022 and series 4 bonds to June 18, 2022. DAYLI Partners is investing through Daily Empowering Bio Healthcare Fund 3 and IBK Capital Corporation is investing through IBK Fincial Group IP Creation Fund. On July 19, 2019, the company has changed conversion period end date for series 4 bonds to October 18, 2022. The conversion period will start on October 19, 2020 and end on September 18, 2022. On October 17, 2019, the company has changed conversion period end date for series 4 bonds to December 26, 2022. The conversion period will start on October 19, 2020 and end on November 26, 2022. The company expects to close the transaction on December 27, 2019.